1. Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. (October 2018) Authors: Wong, Gabrielle; Zhou, Jin; Liu, Jie; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven; Puschhof, Jens; McFarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit Journal: Nature medicine Issue: Volume 24:Number 10(2018) Page Start: 1627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiomyocyte PKA ablation eliminates cardiac β-adrenergic response without adverse effects on the heart. (March 2020) Authors: Zhang, Ying; Zhang, Xiaoying; Li, Ying; Wang, Wei; Chen, Biyi; Liu, Chong; Ai, Xiaojie; Zhang, Xiaoxiao; Tian, Ying; Zhang, Chen; Tang, Mingxin; Szeto, Christopher; Hua, Xiang; Xie, Mingxin; Zeng, Chunyu; Wu, Yingjie; Zhou, Lin; Houser, Steven; Chen, Xiongwen Journal: Journal of molecular and cellular cardiology Issue: Volume 140(2020)supplement Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study. Issue 2 (10th September 2020) Authors: Drusbosky, Leylah; Nangia, Chaitali; Nguyen, Andrew; Szeto, Christopher; Newton, Yulia; Spilman, Patricia; Reddy, Sandeep Bobby Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗